China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology research center in Abu Dhabi. This new facility, the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre, will offer the firm’s end-to-end AI-driven drug discovery platform, Pharma.AI, and explore aging research and sustainable chemistry.
Research Center Objectives
The aim of the new site is to seek local biotechs and academic partners for license deals and collaborations focused on the application of Insilico’s software products. The center is backed by support from the Abu Dhabi Investment Office (ADIO) and will serve as Insilico’s regional headquarters in Abu Dhabi, an emerging hub for the biotech industry.
Middle East Expansion
Insilico has been building its presence in the Middle East following an August 2022 USD 95 million Series D2 investment round led by Prosperity7 Ventures, affiliated with Saudi Arabia-based VC Aramco Ventures. Additionally, a Memorandum of Understanding has been signed with the Saudi Arabian government to provide Insilico’s end-to-end AI drug discovery platform to local biotech companies, partner on robotic drug discovery, and contribute to local clinical trial expertise, among other projects.-Fineline Info & Tech
